Login / Signup

The impact of apelin and relaxin plasma levels in masked hypertension and white coat hypertension.

Elias SanidasKostas TsakalisDimitrios P PapadopoulosKanella ZervaMaria VelliouDespoina PerreaMarina MantzouraniDimitrios IliopoulosJohn Barbetseas
Published in: Journal of clinical hypertension (Greenwich, Conn.) (2018)
Masked hypertension (HTN) and white coat hypertension represent two reverse forms of clinical HTN with questionable prognostic significance. Recent evidence supports that low apelin and relaxin plasma levels contribute to vascular damage accelerating atherogenesis and predisposing to HTN and cardiovascular (CV) events. The aim of this study was to compare apelin and relaxin plasma levels between patients with masked hypertension (MH) and those with white coat HTN (WCH). Overall, 130 patients not receiving antihypertensive therapy were studied. All patients underwent 24-hour ambulatory BP monitoring (ABPM) and office BP measurements. Plasma apelin and relaxin levels were measured by ELISA method. According to BP recordings, 24 subjects had MH (group A) and 32 had WCH (group B). Apelin (200 ± 111 pg/mL vs 305 ± 127 pg/mL, P < 0.01) and relaxin (35.2 ± 6.7 pg/mL vs 46.8 ± 23.6 pg/mL, P < 0.01) plasma levels were significantly lower in patients with MH compared to those with WCH, respectively. In conclusion, our findings showed that patients with MH had significantly lower apelin and relaxin levels compared to those with WCH. This observation implies an additional prognostic role for adipokines supporting the concept that MH is closer to essential HTN whereas WCH is a more benign condition.
Keyphrases
  • blood pressure
  • end stage renal disease
  • chronic kidney disease
  • ejection fraction
  • hypertensive patients
  • prognostic factors
  • stem cells
  • arterial hypertension
  • solid state